Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jan 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for female androgenetic alopecia, commonly known as female pattern hair loss. The two methods being compared are microneedling, which involves using tiny needles to stimulate the scalp, and autologous concentrated growth factor (CGF), a treatment that uses a sample of the patient’s own blood to promote hair regrowth. The goal is to see which of these treatments is more effective in helping women regain their hair.

To be eligible for this trial, women aged 18 to 65 who have been diagnosed with female pattern hair loss can participate. They should not have undergone any laser treatments for hair loss in the past six months and must be willing to share pictures and attend follow-up appointments. Participants can expect to receive either treatment and will be monitored over time to assess hair regrowth. It’s important to note that women with certain serious health conditions or skin infections might not qualify for the study. This trial is currently recruiting participants, so if you meet the criteria and are interested, you could consider joining!

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. age between 18 and 65 years;；
• • 2. clinical diagnosis of female pattern hair loss；
• • 3. no previous laser treatments for AGA in the past six months before enrollment； 4) willingness to provide pictures and follow-up studies.
• Exclusion Criteria:
• • 1. if presented with severe diseases of internal organs, eyes, or skin;
• • 2. inflammation, infection, or unhealed wounds on the skin around the site of treatment on the head;
• • 3. systematic treatment with corticosteroids or other immunosuppressants and immunomodulators in the past 3 months.